Open Access
Potential Mortality Reduction With Optimal Implementation of Angiotensin Receptor Neprilysin Inhibitor Therapy in Heart Failure
Jama CardiologyPeer ReviewedGregg C. Fonarow +32016Journals
Angiotensin receptor neprilysin inhibition (ARNI) therapy provided incremental survival benefit to patients with heart failure and reduced ejection fraction (HFrEF) in clinical trials. To date, estimation of the potential benefits that could be gained from optimal implementation of ARNI therapy at the population level have not been quantified.

The content you want is available to Zendy users.

Already have an account? Sign in
Having issues? Contact support